Journal History
| 2011 | The inaugural issue was released. JPM was published as a quarterly journal. |
| 2013 | JPM was indexed in Scopus (Elsevier), starting with Volume 1 (Issue 1). |
| 2014 | JPM was indexed in PubMed and PubMed Central (PMC). |
| 2016 | JPM announced the first edition of the Travel Awards. |
| 2018 | JPM was indexed in Emerging Sources Citation Index (ESCI)—Web of Science (Clarivate Analytics), starting with Volume 1 (Issue 1). JPM received its first CiteScore (2017) of 2.62, ranked 54/189 (Q1) in "Medicine (miscellaneous)". |
| 2019 | JPM was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 1 (Issue 1), ranked in Q1. |
| 2020 | JPM received its First Impact Factor (4.433), ranked 10/102(Q1) in the category "Health Care Sciences & Services", 24/165(Q1) in the category "Medicine, General & Internal". |
| 2021 | JPM adopted a monthly publication schedule. JPM received its 2020 Impact Factor (4.945), ranked 15/108(Q1) in the category "Health Care Sciences & Services", 31/169(Q1) in the category "Medicine, General & Internal". |
| 2022 | JPM received its 2021 Impact Factor (3.508), covered in the category "Health Care Sciences & Services" and "Medicine, General & Internal". JPM organized the first webinar "Radiation Response Biomarkers for Individualised Cancer Treatments". JPM established the following sections: -Personalized Therapy and Drug Delivery; -Evidence Based Medicine; -Regenerative Medicine and Therapeutics; -Epigenetic Therapy; -Sex, Gender and Hormone Based Medicine. |
| 2023 | JPM has established the following sections: -Disease Biomarker; -Life Stage Specific Medicine (LSSM); -Personalized Critical Care; -Molecular Targeted Therapy. |
| 2024 | Inter-American Society for Minimally Invasive Spine Surgery (SICCMI) became affiliated to JPM. Korean Society of Brain Neuromodulation Therapy (KBNT) became affiliated to JPM. American Board of Precision Medicine (ABOPM) became affiliated to JPM. |
Editor-in-Chief
| 2011–2015 | Editor-in-Chief: Prof. Dr. Urs A. Meyer |
| 2015–2021 | Editor-in-Chief: Prof. Dr. Stephen B. Liggett |
| 2021–2024 | Editor-in-Chief: Prof. Dr. David Alan Rizzieri |
| 2024–present | Editor-in-Chief: Prof. Dr. Kenneth P.H. Pritzker |
Section Editor-in-Chief
| 2021–2023 | Section Editor-in-Chief: Prof. Dr. Richard E. Frye for the section on Mechanisms of Diseases |
| 2021–present | Section Editor-in-Chief: Prof. Dr. Enrico Mini for the section on Pharmacogenetics Section Editor-in-Chief: Prof. Dr. Kenneth P.H. Pritzker for the section on Clinical Medicine, Cell, and Organism Physiology Section Editor-in-Chief: Prof. Dr. K. Ray Chaudhuri for the section on Methodology, Drug and Device Discovery |
| 2022–present | Section Editor-in-Chief: Prof. Dr. Salvatore Scacco for the section on Omics/Informatics Section Editor-in-Chief: Prof. Dr. Marijn Speeckaert for the section on Epidemiology Section Editor-in-Chief: Prof. Dr. Liang Cheng for the section on Personalized Therapy and Drug Delivery Section Editor-in-Chief: Prof. Dr. Taulant Muka for the section on Evidence Based Medicine |
| 2023–present | Section Editor-in-Chief: Prof. Dr. Lorenza Rimassa for the section on Disease Biomarker Section Editor-in-Chief: Prof. Dr. Weikuan Gu for the section on Life Stage Specific Medicine (LSSM) Section Editor-in-Chief: Prof. Dr. Yves A. Lussier for the section on Mechanisms of Diseases |
| 2023–2024 | Section Editor-in-Chief: Prof. Dr. Anat Biegon for the section on Sex, Gender and Hormone Based Medicine |
